Auxilium completes individual enrollment in XIAFLEX stage III trial against Peyronie’s disease Auxilium Pharmaceuticals, Inc. We are happy to do this important advancement milestone in Peyronie’s disease and progress what can potentially be considered a second indication for XIAFLEX, said Armando Anido, CEO and President of Auxilium tadora.biz . We believe completing the enrollment of over 600 individuals at sites in the U.S. And Australia in under half a year speaks to the enthusiasm in the urology community and their potential patients for a nonsurgical treatment alternate. We anticipate reporting top-line outcomes in the 1st half of 2012.S.